Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (210 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (228 journals)
    - DENTISTRY (288 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (119 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (182 journals)
    - GERONTOLOGY AND GERIATRICS (132 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (98 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (136 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (164 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (152 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (190 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (150 journals)

RESPIRATORY DISEASES (102 journals)                     

Showing 1 - 102 of 102 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 254)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 16)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 4)
BMJ Open Respiratory Research     Open Access   (Followers: 5)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal  
Canadian Respiratory Journal     Open Access   (Followers: 2)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 100)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 2)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 38)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 11)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 3)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 17)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 32)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 37)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  

           

Similar Journals
Journal Cover
Breathe
Journal Prestige (SJR): 0.465
Citation Impact (citeScore): 1
Number of Followers: 4  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1810-6838 - ISSN (Online) 2073-4735
Published by European Respiratory Society Homepage  [4 journals]
  • Biomarkers in respiratory diseases

    • Authors: Dobler; C. C.
      Pages: 265 - 266
      Abstract: The December issue of Breathe focuses on biomarkers in respiratory diseases [1–4]. Biomarkers are measurable indicators of the presence, severity or type of a disease. They can help us understand the cause, phenotype, progression or regression, prognosis, or outcome of treatment of a disease. Biomarkers hold the promise of personalised ­medicine, which aims to tailor treatments to ­individual patients based on their biomarker profile and, by doing so, reduce the harms from ineffective treatments and increase the benefits from effective treatments. Biomarkers to describe disease ­phenotypes and to determine optimal treatments based on these phenotypes are ­receiving ­substantial attention in the current respiratory research literature. The search for clinically useful biomarkers that impact clinical decision-making is, however, challenging, and the vast majority of biomarkers are failing at the initial verification and validation stages before they enter clinical practice [5].
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0329-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Advanced roles in respiratory healthcare science: it's not just spirometry

    • Authors: Shakespeare, J; Parkes, E, Bryce, M, Hull, J.
      Pages: 267 - 269
      Abstract: Advanced clinical practitioner (ACP) roles in nursing began as early as the 1970s. Health Education England, along with National Health Service (NHS) Improvement and NHS England, have recently published a definition of and standards for multiprofessional advanced clinical practice [1]. They define these practitioners as "experienced, registered health and care practitioners...a level of practice characterised by a high degree of autonomy and complex decision making...underpinned by a masters level award or equivalent." These roles are now common place in healthcare professions such as nursing, physiotherapy and occupational therapy.
      Keywords: Respiratory clinical practice
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0310-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Interstitial lung diseases: course report

    • Authors: Kreuter, M; Wells, A, Mehta, D. R, Kovchun, A.
      Pages: 270 - 272
      Abstract: In 2014, the European Respiratory Society (ERS) realised the need to improve medical education in the field of rare lung disease, especially in interstitial lung diseases (ILDs). Since then, four ERS courses have been held in Heidelberg, Germany, and provided an overview of the field of ILDs. The latest ERS course on ILD was again held in Heidelberg in April 2019 and 80 participants from 27 different countries took part. New this year, the course was streamed live to over 100 participants from 31 countries. Over the years, the organisers' and the ERS's ambition has been to improve the interactivity and the interdisciplinary aspects of this course. To address this, the participants learnt which diagnostic procedures should be applied for approaching ILDs and what difficulties may arise in ILD diagnosis, which were discussed based on real-life cases. Special emphasis was given to practical courses including high-resolution computed tomography (CT) evaluation and sessions on ILD pathology, and a hands-on session on cryobiopsy. As therapy remains a challenging aspect in the management of ILDs, this course provided participants with insights into the newest developments, and the pros and cons of specific ILD treatments; in addition, end-of-life strategies and acute complications were approached in workshops. Interdisciplinary ILD board discussions were held between specialists and course participants, and course attendees had the opportunity to present their own challenging cases and discuss them with leading experts. Furthermore, there was a dedicated session on the pathogenesis and future trends in ILDs as well as specific conditions and treatments for ILDs.
      Keywords: Interstitial and orphan lung disease
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0259-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • {beta}2-agonists do not work in children under 2 years of age: myth or
           maxim'

    • Authors: Yusuf, F; Prayle, A. P, Yanney, M. P.
      Pages: 273 - 276
      Abstract: The question of whether infants
      Keywords: Asthma and allergy, Paediatric pulmonology
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0255-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Biomarker development in asthma from a patient's perspective

    • Authors: Hamerlijnck; D.
      Pages: 277 - 278
      Abstract: I was finally diagnosed in 1981 with asthma after having had lung problems since childhood. My asthma diagnosis involved a hospital admission to do a lot of tests. At that time, I had no idea what it was all about. I thought that a hospital admission was normal for diagnosing asthma. I underwent allergy tests, bronchoscopy, contrast fluid chest radiography and a lot of blood and sputum tests... and many more. But what exactly they were looking for and what it meant, I had no idea.
      Keywords: Asthma and allergy
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0303-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Continuous professional development: elevating thoracic oncology education
           in Europe

    • Authors: van Geffen, W. H; Blum, T. G, Aliberti, S, Blyth, K. G, Bostantzoglou, C, Farr, A, Grigoriu, B, Hardavella, G, Huber, R. M, Maskell, N, Massard, G, Rahman, N. M, Stolz, D, van Meerbeeck, J.
      Pages: 279 - 285
      Abstract: Thoracic oncology encompasses a broad spectrum of primary tumour entities originating from various pulmonary, tracheobronchial, pleural, mediastinal and chest wall tissues or distinct cell types within these compartments. Lung cancer represents by far the most frequent malignant tumour within the thoracic cavity, and is the most common type and largest killer among all cancers worldwide. Lung cancer leads mortality statistics in Europe, accounting for at least one fifth of all cancer-related deaths [1]. In addition, lung cancer causes a significant burden of symptoms in a population of patients with high comorbidity, providing significant challenges to national healthcare systems in the European Union, with the highest overall costs among all cancer types [2–4]. Contrary to the general stigma applied to lung cancer patients, where they are often assumed to suffer from a self-inflicted disease, it is now estimated that up to 10–20% of lung cancer patients are never-smokers [5, 6]. Even if numerically far lower, the remaining
      Keywords: Lung cancer
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0296-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Hot topics and current controversies in non-cystic fibrosis bronchiectasis

    • Authors: Severiche-Bueno, D; Gamboa, E, Reyes, L. F, Chotirmall, S. H.
      Pages: 286 - 295
      Abstract: Non-cystic fibrosis bronchiectasis (NCFB) is a neglected and orphan disease with poor advances through the 20th century. However, its prevalence is rising and with this come new challenges for physicians. Few guidelines are available to guide clinicians on how to diagnose and manage patients with NCFB. Many areas of debate persist, and there is lack of consensus about research priorities most needed to advance patient care and improve clinical outcomes. In this review, we highlight the current hot topics in NCFB and present updated evidence to inform the critical areas of controversy.Key points
      Postural drainage, active cycle of breathing techniques and pulmonary rehabilitation are non-pharmacological treatment options that should be offered to all patients with non-cystic fibrosis bronchiectasis (NCFB).
      Eradication of Pseudomonas aeruginosa (PA) colonisation in patients without an acute exacerbation remains debatable.
      Sputum cultures are the leading and most readily available tool to detect patients with chronic colonisation by PA and should be performed in all patients with NCFB.
      Antibacterial monoclonal antibodies and vaccine studies have shown promising results in the prevention of chronic colonisation with PA and should stimulate new studies in NCFB.
      NCFB patients colonised with PA are at more risk of a rapid decline in lung function, worsening quality of life and more hospital admissions.
      Dual therapy is a promising option for the management of patients with PA-related exacerbations.
      Patients with PA-related exacerbations benefit from prolonged courses of antibiotics (i.e. 14 days) but emerging and future studies, including dual therapy, may show promising results with shorter courses.
      Endophenotyping bronchiectasis to address its inherent heterogeneity is a promising avenue for future investment and research.
      Keywords: CF and non-CF bronchiectasis
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0261-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Procalcitonin in respiratory disease: use as a biomarker for diagnosis and
           guiding antibiotic therapy

    • Authors: Creamer, A. W; Kent, A. E, Albur, M.
      Pages: 296 - 304
      Abstract: Procalcitonin (PCT) is a peptide measurable in serum which becomes elevated in response to bacterial infection. Multiple trials have explored the safety and efficacy of using PCT as a biomarker to guide decisions about starting or stopping antibiotic therapy in a wide variety of situations, and PCT assays have recently been approved by the Federal Drug Administration (FDA) in the US for use in both sepsis and respiratory tract infections. While there have been a number of promising results particularly in acute respiratory tract infections and intensive care unit settings, problems including adherence to protocol, cost of the assay and improved antimicrobial stewardship more generally, have limited more widespread adoption.This educational article summarises the evidence for the use of procalcitonin as a biomarker of bacterial infection across the spectrum of respiratory disease and reviews how the use of procalcitonin-guided antibiotic therapy is reflected in current major international guidelines.Key points
      Procalcitonin has been widely investigated as a biomarker of bacterial infection to aid diagnosis and decisions to start or stop antibiotics in a range of conditions, including in diseases of the lower respiratory tract.
      Meta-analysis suggests that the use of procalcitonin to guide antibiotic therapy in acute respiratory tract infections can reduce duration of antibiotic therapy and hospital admission without adversely affecting outcomes – however, there was significant heterogeneity in methodology and population in the included studies, and more recent studies have failed to show such significant benefits.
      The use of procalcitonin to guide stopping or shortening antibiotic therapy in sepsis/septic shock is suggested in the international guidelines for the management of sepsis (2016), but this is a "weak" recommendation, with a low quality of evidence recognised. Major international guidelines do not support a role for procalcitonin in the management of acute exacerbations of COPD, bronchiectasis, interstitial lung disease or pleural infection.
      Regardless of situation, decisions on initiating, altering, or discontinuing antimicrobial therapy should never be made solely on the basis of changes in any biomarker – while biomarkers such as procalcitonin may provide supportive information, they should only be used alongside regular and robust clinical assessment.Educational aims
      To understand the principles of using procalcitonin to guide decisions regarding antibiotic use (procalcitonin-guided antibiotic therapy).
      To review important research studies into the use of procalcitonin as a biomarker of bacterial infection across the spectrum of diseases of the lower respiratory tract.
      To understand the current international guidelines regarding procalcitonin use in disease of the lower respiratory tract.
      Keywords: Respiratory infections and tuberculosis
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0258-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Clinical utility of exhaled nitric oxide fraction in the management of
           asthma and COPD

    • Authors: Turner, S. W; Chang, A. B, Yang, I. A.
      Pages: 306 - 316
      Abstract: Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged>5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.Key points
      For individuals aged ≥12 years, FENO is not recommended by all guidelines as a test to diagnose asthma (recommended only by the UK National Institute for Health and Care Excellence guideline for asthma symptoms, which are likely to respond to corticosteroid treatment).
      FENO may be used in conjunction with other investigations to diagnose asthma in 5–16-year-olds where there is diagnostic uncertainty, but further evidence is required.
      FENO is not recommended as a routine test to monitor all patients with asthma or to titrate asthma treatment.
      FENO is not recommended for routine clinical testing in adults with COPD.
      FENO may be useful to identify patients with COPD who could benefit from the use of inhaled corticosteroids (asthma–COPD overlap).Educational aims
      To understand what factors other than asthma and COPD affect FENO
      To understand the current controversies in the application of FENO to diagnosis and management of asthma in children
      To understand the current controversies in the application of FENO to diagnosis and management of asthma and COPD in adults
      Keywords: COPD and smoking, Asthma and allergy
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0268-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • COPD treatment choices based on blood eosinophils: are we there yet'

    • Authors: Oliver, B; Tonga, K, Darley, D, Rutting, S, Zhang, X, Chen, H, Wang, G.
      Pages: 318 - 323
      Abstract: Eosinophils are increasingly being recognised as an important characteristic feature of COPD. Patients with COPD and eosinophilic inflammation tend to respond to steroid therapy; however, many questions remain regarding the optimum measurement. Eosinophilic inflammation may be defined based on various sampling techniques, including eosinophil levels in blood, sputum, bronchoalveolar lavage or biopsy, which leads to inconsistencies in its definition. Blood eosinophils may increase in conjunction with sputum eosinophils during COPD exacerbations and therefore may be a good surrogate marker of airway eosinophilic inflammation. However, the timing of the blood eosinophil measurement, the stability of the eosinophil count and the threshold used in different studies are variable. The use of blood eosinophil count to direct biological therapies in COPD has also had variable outcomes. Eosinophilic inflammation has an important role in COPD management; however, its use as the optimum biomarker still needs further investigation.Key points
      Eosinophilia may play a significant role in the pathogenesis of COPD.
      Eosinophilic inflammation in COPD can be steroid responsive; however, eosinophilic inflammation is variable, and caution needs to be taken with measurements and the thresholds used.
      The long-term effects of reducing eosinophil levels in COPD is unclear.Educational aims
      To explore current knowledge of eosinophils in COPD.
      To explore the relationship between eosinophilia and corticosteroid use.
      To understand the limitations of assessing and using eosinophilia in COPD.
      Keywords: COPD and smoking
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0254-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • A Malaysian ex-smoker with cough, breathlessness and nonresolving
           bronchospasm

    • Authors: Lim, J. A; Caruppaiya, N, Zainol Abidin, N, Khor, B. T, Palanivelu, T, Hukam Gopal Chand, S. D, Ibrahim, A.
      Pages: 324 - 329
      Abstract: A 60-year-old, Malaysian ex-smoker with no known medical illness was referred from a district hospital for severe acute exacerbation of COPD secondary to pneumonia. He had a 40-pack-year history of smoking but had quit smoking for the past 2 years.
      Keywords: COPD and smoking
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0224-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • In the spotlight: first ERS Early Career Member Award winner, the ERS Lung
           Science Conference 2020 and new ECMC members

    • Authors: Janssens, T; Burgy, O, Rolandsson Enes, S, De Brandt, J, on behalf of all newly incoming ECMC members
      Pages: 330 - 336
      Abstract: At the European Respiratory Society (ERS) International Congress in Paris (France) in 2018, the Early Career Members Committee (ECMC) postulated the idea of providing an incentive for ambitious and successful Early Career Members (ECMs) through granting an ECM award. The ECMC forwarded the concept to the ERS Executive Committee. ECM representatives of each assembly discussed the nomination of an ECM within each assembly. Based on their curriculum vitae and involvement within ERS, the nominees were ranked, and Lies Lahousse became the laureate of the first ERS Early Career Member Award (figure 1). Two ECMs (T. Janssens and J. De Brandt) visited Prof. Lahousse in Ghent (Belgium) to interview her.
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0253-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Changes in FEV1 over time in COPD and the importance of spirometry
           reference ranges: the devil is in the detail

    • Authors: Kirkby, J; Nenna, R, McGowan, A.
      Pages: 337 - 339
      Abstract: Spirometry plays a pivotal role in the diagnosis and management of COPD and other respiratory diseases. Since lung function varies with age, height, sex and ethnicity, accurate interpretation is dependent upon using appropriate reference ranges. In this article, we will present two landmark papers: one on changes in forced expiratory volume in 1 s (FEV1) over time in COPD [1] and the other focussing on spirometry reference ranges produced by the Global Lung Function Initiative (GLI) [2].
      Keywords: COPD and smoking, Lung structure and function
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0252-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Model for predicting EGFR mutation status in lung cancer

    • Authors: Nguyen Ho, L; Le, T. V.
      Pages: 340 - 342
      Abstract: Lung cancer is a leading cause of cancer-related mortality worldwide, with an estimated 1.38 million deaths annually [1]. The approach to diagnosis and treatment has changed considerably, with developments such as 1) screening of lung cancer to identify the early stage lesions, 2) various sampling methods to diagnose the histopathological features of the lung tumour, and 3) changing from conventional chemotherapy to molecular targeted therapy. In the era of precision medicine, targeted therapy consistent with specific oncogenic mutation, such as tyrosine kinase inhibitor (TKI) treatment in lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation, has an important role.
      Keywords: Lung cancer
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0250-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Could airway basal cells be a novel predictor of mortality in IPF'

    • Authors: Organ; L.
      Pages: 343 - 345
      Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease that exhibits a variable trajectory, depending on the individual [1]. Currently, it is very difficult to predict the prognosis of IPF, making the clinical management of the disease a major challenge. Over the years, there have been numerous studies to identify peripheral blood biomarkers, gene variants or clinical features of IPF that correlate to disease outcome [2, 3]. We now understand that the development and progression of IPF occurs due to an abnormal regenerative response in response to damaged epithelium [4]; however, there has been very limited research into specific changes or potential biomarkers that reflect the mechanism of alveolar derangement and disease progression. Whilst lung biopsies taken at diagnosis would be ideal to investigate for potential alveolar-derived biomarkers, they are highly invasive and can be high risk to the patients' health due to post-operative complications. They therefore tend to be avoided in clinic. Bronchoalveolar lavage (BAL), on the other hand, is a minimally invasive procedure, while still providing a sample of the cellular environment with the alveolar region of the lung. Therefore, Prasse et al. [5] sought to investigate the gene expression of BAL samples from IPF patients to address this problem.
      Keywords: Interstitial and orphan lung disease
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0265-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Management of incidental nodules in lung cancer screening: ready for
           prime-time'

    • Authors: Kanellakis, N. I; Lamote, K.
      Pages: 346 - 349
      Abstract: Lung cancer is the leading cause of cancer-related mortality. Two independent trials from the USA and the Netherlands and Belgium demonstrated that annual low-dose computed tomography (LDCT) screening reduced mortality by 20% and 26%, respectively [1–3]. LDCT is therefore widely accepted as the preferred method for detecting pulmonary nodules, but raises an important clinical challenge concerning nodule evaluation and patient management [4–7]. Current pulmonary nodule evaluation and clinical management starts by estimating the probability of cancer (pCA) based on clinical (age, symptoms, smoking history, performance status, associated lung diseases, family history and previous clinical history) and radiological (size, growth and morphology) parameters, and takes into account the patient's preferences. Certain lung nodule features suggest a high likelihood of malignancy (such as spiculation, lobulation and pleural retraction) whereas others favour a benign aetiology (internal fat, calcifications and round shape) [8–10]. Furthermore, the likelihood of malignancy and nodule diameter are positively correlated. However, nodule size is not a reliable standalone malignancy biomarker as slow growing adenocarcinoma nodules will appear small, and benign lesions may show growth and volume doubling time in the range of malignant nodules [11]. Hence, the assessment of pulmonary nodules remains a diagnostic challenge. Cohorts with low to moderate malignancy risk lung nodules pose the clinical dilemma between invasive procedures and serial surveillance. A score that could reliably predict pulmonary nodule aetiology would improve patient management by minimising the number of invasive procedures and reducing healthcare costs and patients' discomfort [12]. To this end, patients with a probably benign nodule could be managed by serial surveillance avoiding invasive tests, whereas those patients with a probably malignant nodule could be stratified to the most appropriate treatment more quickly [13]. These authors previously developed a biomarker-driven lung nodule classifier based upon 222 subjects [14]. In this study, Silvestri et al. [15]. designed and implemented a multicentre, double-blinded, prospective, observational study with a retrospective evaluation to validate the accuracy of this lung nodule classifier.
      Keywords: Lung cancer
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0247-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Initial inhaler choice in COPD: real-world evidence

    • Authors: Jones; T.
      Pages: 350 - 352
      Abstract: Long-acting bronchodilators are the mainstay of inhaled therapy in COPD. Both long-acting β-agonists (LABA) and long-acting muscarinic antagonists (LAMA) are effective at reducing breathlessness and exacerbation frequency, with LAMA being the more effective of the two classes [1]. The Global Initiative for Chronic Obstructive Lung Disease advises that inhaled corticosteroids (ICS) are reserved for those who exacerbate more frequently and preferably after the addition of dual long-acting bronchodilators [2]. Some people with COPD benefit from ICS, and there is evidence that blood eosinophil count is a useful biomarker to highlight who might benefit [3]. ICS are known to increase the risk of pneumonia in people with COPD [4] but despite the guidelines, many people with COPD are prescribed LABA/ICS combinations as initial inhaled therapy [5]. Suissa et al. [6] reported real-world evidence comparing LABA/ICS with LAMA as the initial treatment of COPD, stratified by blood eosinophil count, detailing both the benefits for exacerbation frequency and risk of pneumonia with each treatment strategy.
      Keywords: COPD and smoking, Pulmonary pharmacology and therapeutics
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0256-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Can we use a biomarker to guide antibiotic treatment in severe COPD
           exacerbations'

    • Authors: Adepoju; V. A.
      Pages: 353 - 355
      Abstract: Prins HJ, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J 2019; 53: 1802014.
      Keywords: COPD and smoking, Respiratory infections and tuberculosis
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0257-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • Assembly 14: clinical techniques, imaging and endoscopy

    • Authors: De Wever; W.
      Pages: 356 - 357
      Abstract: Assembly 14 (clinical techniques, imaging and endoscopy) is the youngest assembly of the European Respiratory Society (ERS). Because the increasing role of interventional pulmonology in diagnosis and treatment, and the role of imaging as key element in the diagnosis of many diseases, these two groups were growing, and the moment came that they became a new assembly. Assembly 14 accommodates the following groups.
      Keywords: Lung imaging
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.0218-2019
      Issue No: Vol. 15, No. 4 (2019)
       
  • "Protect your lungs: get vaccinated." Breathe 2019; 15: 263-264.

    • Pages: 358 - 358
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.ELF553
      Issue No: Vol. 15, No. 4 (2019)
       
  • Pulmonary Embolism

    • Pages: 360 - 365
      Abstract: The chances of a full recovery from a pulmonary embolism are higher the sooner it is spotted. Symptoms can include
      PubDate: 2019-12-01T08:30:12-08:00
      DOI: 10.1183/20734735.ELF154
      Issue No: Vol. 15, No. 4 (2019)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.227.2.246
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-